Latent Tuberculosis Infection (LTBI)
Stopping TB requires a government program that functions every day of the year, and that's hard in certain parts of the world. And partly it's because of who tuberculosis affects: It tends to affect the poor and disenfranchised most - Tom Frieden
HWN Suggests
‘Latent’ Tuberculosis? It’s Not That Common, Experts Find
Although experts frequently assert that nearly 1.7 billion people carry dormant tuberculosis worldwide, that figure may be a “gross exaggeration” of the real threat, a recent study concludes. The study, published last month in the journal BMJ, found that nearly everyone who falls seriously ill with TB does so within two years of getting infected. So-called latent infections only rarely become active, even in old age. Researchers “have spent hundreds of millions of dollars chasing after latency, but the whole idea that a quarter of the world is infected with TB is based on a fundamental misunderstanding,” said Dr. Lalita Ramakrishnan, a tuberculosis expert at the University of Cambridge…
Articles of Interest
Clinical Overview of Latent Tuberculosis Infection
Finding and treating people with latent TB infection is essential for controlling and eliminating TB disease in the United States. Treatment for latent TB infection is effective for preventing TB disease.
Diagnosis for Latent Tuberculosis Infection: New Alternatives
Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) and the interferon gamma release assay (IGRA) are currently used to establish the diagnosis of LTB. However, neither TST nor IGRA is useful to discriminate between active and latent tuberculosis. Moreover, these tests cannot be used to predict whether an individual with LTBI will develop active tuberculosis (TB) or whether therapy for LTBI could be effective to decrease the risk of developing active TB.
Is this the answer to latent TB?
Only 10% of people with latent tuberculosis go on to develop the active disease. Monica Desai asks who stands to benefit if the latest research bears fruit.
Latent TB treatment
Prevention is better than cure. About 1 in 10 people with latent TB will develop active TB. And there is no way to know if you will be one of them. It is possible to become ill with active TB many years after you breathe in TB bacteria. Treatment is the only way to remove the TB bacteria from your body.
Latent tuberculosis infection: An overview
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB) disease. Individuals with LTBI represent a reservoir for active TB cases.
Management of Latent Tuberculosis Infection
Three months of weekly isoniazid and rifapentine is strongly recommended in all adults with LTBI. Compared with 9 months of isoniazid, weekly isoniazid and rifapentine for 3 months had higher completion rates (82% vs 69% [P < .001]), fewer serious adverse events (1.6% vs 2.9% [P < .001]), and less hepatotoxicity (0.4% vs 2.7% [P < .001]) when administered via directly observed therapy, which occurs when a health care worker directly observes an individual taking their prescribed medication.
Management of Latent Tuberculosis Infection
Four Months of Daily Rifampin - Rifamycin-based regimens are preferred therapy because they are effective, safe, and associated with higher adherence rates than longer isoniazid regimens.
Treatment Regimens for Latent TB Infection
There are several treatment regimens recommended in the United States for latent TB infection. The medications used to treat latent TB infection include the following: Isoniazid (INH), Rifapentine (RPT), Rifampin (RIF),
Resources
StatPearls
In high-income countries with a low prevalence of tuberculosis, public health interventions focus on detecting and treating patients with latent tuberculosis (TB) infection. Latent TB infection may reactivate to cause active and infectious TB disease that can spread throughout the population. Identification and characterization of individuals with latent TB infection and at risk of reactivation is imperative for public health but requires balancing the benefits of therapy with potential harms.
